Study of Blood and Eye Fluid Biomarkers in Patients with Choroidal Neovascularization and Their Response to Anti-VEGF Treatment

What this Trial Is About

This research aims to find biomarkers in the blood and eye fluid of patients with type 1 choroidal neovascularization CNV, a condition linked to age-related macular degeneration AMD and central serous chorioretinopathy. The study evaluates how these biomarkers relate to patients responses to anti-VEGF treatment, which is commonly used but not fully effective for all patients. The investigation also explores the role of the mineralocorticoid receptor pathway in CNV development to better understand disease mechanisms and potential treatment markers. Participants include two groups patients with CNV related to AMD or central serous chorioretinopathy, and a control group without CNV who have undergone eye surgery such as cataract or vitrectomy. The study involves collecting blood and aqueous humor samples to analyze metabolites linked to the mineralocorticoid receptor pathway. These biomarker analyses are conducted over a 24-month period to compare findings between groups and assess treatment response. During the study, participants undergo blood and eye fluid sampling along with clinical evaluations. Researchers monitor biomarkers and correlate them with treatment outcomes over two years. The main measures focus on biomarker levels in the blood and aqueous humor, while secondary assessments look at how these biomarkers relate to anti-VEGF treatment response. This observational study does not involve administering treatments but collects data to improve understanding of CNV and its management.

Biomarkers and Choroidal Neovascularization